The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Open accessAbstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms. CONCLUSIONS: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status. CLASSIFICATION OF EVIDENCE: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Although clinical trials of the Aβ-directed mAb Bapinezumab showed no clear cognitive benefits in patients with mild to moderate AD [42], the results also indicated that APOE ε4 carrier status may limit the response to anti-Aβ passive immunization [43,44], as well as being associated with an increased rate of microbleeds and vasogenic edema [45].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [44]
In the citing paper
“in phase II trials, the anti-Aβ antibody bapineuzumab reduced CSF phospho-tau levels in patients with AD182,183”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [183]
In the citing paper
“In fact, there have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies (74-79).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Self-citationNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Self-citation
Cited by
Sorted by citations
Items 501–600 of 752
An optimistic approach to nanotechnology in Alzheimer's disease management: An overview
Tiwari, V., Tiwari, A., Sharma, A., Kumar, M., Kaushik, D. K., & Sagadevan, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104722 · Cited by 13
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Høilund‐Carlsen, P. F., Alavi, A. A., & Barrio, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240206 · Cited by 12
Dumurgier, J., Laplanche, J., Mouton‐Liger, F., Lapalus, P., Indart, S., Prévot, M., Peoc’h, K., Hugon, J., & Paquet, C. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7335-6 · Cited by 14
Valls-Comamala, V., Guivernau, B., Bonet, J., Puig, M., Perálvarez‐Marín, A., Palomer, E., Fernàndez‐Busquets, X., Altafaj, X., Tajes, M., Puig‐Pijoan, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17074 · Cited by 13
Translational Research in Neurology
Honig, L. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2883 · Cited by 13
Self-citationHenley, D. B., Sundell, K. L., Sethuraman, G., & Siemers, E. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2413 · Cited by 13
Validation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities
Bechten, A., Wattjes, M. P., Purcell, D. D., Aliaga, E. S., Daams, M., Brashear, H. R., Arrighi, H. M., & Barkhof, F. (2017) · Journal of Neuroimaging · doi:10.1111/jon.12422 · Cited by 13
Clinical trials in Alzheimer's disease
Delrieu, J., & Vellas, B. J. (2015) · Wiley eBooks · doi:10.1002/9781118323434.ch9 · Cited by 13
Shirzadi, Z., Schultz, A. P., Properzi, M. J., Yaari, R., Yau, W.-Y. W., Brickman, A. M., Rafii, M. S., Donohue, M., Ernstrom, K. B., Wang, S., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.139 · Cited by 13
Self-citationRecent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 16
Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?
Matsumoto, Y., & Kohyama, K. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s49923 · Cited by 12
Hara, H., Mouri, A., Yonemitsu, Y., Nabeshima, T., & Tabira, T. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.057 · Cited by 13
Alzheimer’s Disease Clinical Trials: Changing the Paradigm
Cummings, J. L. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0234-y · Cited by 12
Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990141 · Cited by 12
Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.
Fan, L., & Chiu, M. (2010) · PubMed · Cited by 11
Bapineuzumab in Alzheimer's disease: where now?
Wilcock, G. K. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70359-x · Cited by 12
Drug Treatments in Development for Alzheimer's Disease
Woodward, M. C. (2012) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2012.tb00133.x · Cited by 12
van Etten, E. S., Mahinrad, S., Grill, J. D., Salloway, S., Atri, A., Cogswell, P. M., Benzinger, T. L. S., Iwatsubo, T., Iadecola, C., Lemere, C. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71361 · Cited by 16
Self-citationPhRMA Survey of Pharmacogenomic and Pharmacodynamic Evaluations: What Next?
Grecco, N., Cohen, N., Warner, A. W., López-Correa, C., Truter, S. L., Snapir, A., Piccoli, S. P., Wang, D., Westelinck, A., Hinman, L. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.334 · Cited by 11
Yaari, R., Holdridge, K. C., Choi, J. S., Donohue, M., Kantarci, K., Jack, C. R., Zuk, S. M., Sims, J. R., Johnson, K. A., Aisen, P. S., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.56 · Cited by 15
Self-citationAmyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
Vyas, J., Raytthatha, N., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00023-6 · Cited by 13
Hampel, H. J., & Prvulovic, D. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0021-4 · Cited by 11
Aberrant protein structure and diseases of the brain
Welzel, A. T., & Walsh, D. M. (2010) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-010-0606-z · Cited by 11
Lu, M., & Brashear, H. R. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.584 · Cited by 11
APOE genotype and Alzheimer’s immunotherapy
Pankiewicz, J. E., & Sadowski, M. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17990 · Cited by 11
Gregory, J. L., Prada, C. M., Fine, S., Garcı́a-Alloza, M., Betensky, R. A., Arbel‐Ornath, M., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182729845 · Cited by 11
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
Creed, M. C., & Milgram, N. W. (2010) · AGE · doi:10.1007/s11357-010-9142-z · Cited by 10
Immunotherapy for Alzheimer's disease
Wang, W., Fan, L., Xu, D.-E., Wen, Z., Yu, R., & Ma, Q. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms065 · Cited by 15
Computational Analysis for the Rational Design of Anti-Amyloid Beta (Aβ) Antibodies
Greene, D., Po, T., Pan, J., Tabibian, T., & Luo, R. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b01837 · Cited by 10
Efficacy of antibody-based therapies to treat Alzheimer's disease: Just a matter of timing?
Cedernaes, J., Schiöth, H. B., & Benedict, C. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.05.002 · Cited by 12
Amyloidβ-Related Angiitis Causing Coma Responsive to Immunosuppression
Weiss, S. A., Pisapia, D. J., Mayer, S. A., Willey, J. Z., & Lee, K. (2012) · Case Reports in Pathology · doi:10.1155/2012/678746 · Cited by 10
A brief history of antibody-based therapy
Alpaugh, M., & Cicchetti, F. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104504 · Cited by 10
Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
Andreasen, N., Blennow, K., & Zetterberg, H. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/638379 · Cited by 9
Self-citationNordberg, A. K., Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Blennow, K., Långström, B., & Zetterberg, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-132474 · Cited by 10
Self-citationOtsubo, Y. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.010 · Cited by 9
Camboni, M., Wang, C.-M., Miranda, C. J., Yoon, J. H., Xu, R., Zygmunt, D. A., Kaspar, B. K., & Martin, P. T. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.001 · Cited by 9
Optimizing Diagnosis and Management in mild-to-moderate Alzheimer’s Disease
Galvin, J. E. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.21 · Cited by 9
21st Century Cures Act and similar policy efforts: at what cost?:
Zuckerman, D. M., Jury, N. J., & Silcox, C. (2015) · BMJ · doi:10.1136/bmj.h6122 · Cited by 9
Conquering Alzheimer’s Disease by Self Treatment
McGeer, P. L., & McGeer, E. G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179913 · Cited by 8
Barnes, J., Initiative, A. D. N., Bartlett, J. W., Fox, N. C., & Schott, J. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121936 · Cited by 9
Self-citationLin, L.-F., Liao, M., Xue, X., Zhang, W., Yan, L., Cai, L., Zhou, X., Zhou, X., & Luo, H. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1287-6 · Cited by 10
Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1
Carswell, C. J., Rañopa, M., Pal, S., Macfarlane, R., Siddique, D., Thomas, D. J., Webb, T., Wroe, S. J., Walker, A. S., Darbyshire, J. H., et al. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000339730 · Cited by 9
Effects of External Beam Radiation onIn VitroFormation of Abeta1-42 Fibrils and Preformed Fibrils
Patrias, L. M., Klaver, A. C., Coffey, M. P., Finke, J. M., Digambaranath, J. L., Dang, L., Martinez, A. A., & Loeffler, D. A. (2011) · Radiation Research · doi:10.1667/rr2448.1 · Cited by 9
Fillit, H. M., Cummings, J. L., Neumann, P. J., McLaughlin, T. P., Salavtore, P., & Leibman, C. W. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0310-8 · Cited by 9
Martens, R. M., Bechten, A., Ingala, S., van Schijndel, R. A., Machado, V. B., de Jong, M. C., Sánchez, E., Purcell, D. D., Arrighi, M., Brashear, R. H., et al. (2017) · European Radiology · doi:10.1007/s00330-017-5022-6 · Cited by 9
Ferl, G. Z., Fuji, R. N., Atwal, J. K., Sun, T., Ramanujan, S., & Quartino, A. L. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200302122307 · Cited by 9
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
van der Hoven, J., van Hummel, A., Przybyla, M., Asih, P. R., Gajwani, M., Feiten, A., Ke, Y. D., Ittner, A., van Eersel, J., & Ittner, L. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70845-x · Cited by 9
Enfermedad de Alzheimer: nuevas estrategias terapéuticas
Villegas, S. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.05.023 · Cited by 10
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials
Kennedy, R., Cutter, G., Wang, G., & Schneider, L. S. S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150847 · Cited by 8
Raji, C. A., Torosyan, N., & Silverman, D. H. S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200487 · Cited by 7
Gao, Y., Guo, J., Zhang, F., & Li, Y. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230419095813 · Cited by 7
Prevention of Alzheimer’s Disease: Intervention Studies
Mangialasche, F., Xu, W., & Kivipelto, M. (2013) · InTech eBooks · doi:10.5772/55034 · Cited by 7
Cunningham, E. L., & Passmore, A. P. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.04.013 · Cited by 7
Beyond diagnosis: What biomarkers are teaching us about the “bio”logy of Alzheimer disease
Rabinovici, G. D., & Roberson, E. D. (2010) · Annals of Neurology · doi:10.1002/ana.22020 · Cited by 7
Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use
Burns, L. C., Orsini, L. S., & L’Italien, G. (2013) · Value in Health · doi:10.1016/j.jval.2013.06.007 · Cited by 8
Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease
Adeniji, A. O., Adams, P. W., & Mody, V. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00007-6 · Cited by 7
Rosenberg, R. N., Fu, M., & Lambracht‐Washington, D. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.05.017 · Cited by 7
Les nouveaux traitements de la maladie d’Alzheimer
Delrieu, J., & Vellas, B. J. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.01.018 · Cited by 11
Perlis, R. H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10121738 · Cited by 7
Clinical Trials and Drug Development
Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100301 · Cited by 8
Altered Clearance and Amyloid-Related Imaging Abnormalities
Cogswell, P. M., Burkett, B. J., Johnson, D. R., & Pillai, J. J. (2025) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.12.002 · Cited by 6
Zhang, Y., Yu, W., Zhang, L., & Li, P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2396911 · Cited by 6
Common Polymorphisms in the GSK3 β Gene May Contribute to the Pathogenesis of Alzheimer Disease
Lin, Q., Cao, Y., & Gao, J. (2014) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988714554712 · Cited by 6
Targeting apolipoprotein E for treating Alzheimer’s disease
Bales, K. R., & Paul, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134366 · Cited by 7
China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study
Zhu, Y., Pan, D., He, L., Rong, X., Li, H., Li, Y., Pi, Y., Xu, Y., & Tang, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.797704 · Cited by 6
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Guo, M. H., & Vaishnavi, S. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00750-x · Cited by 6
Cantillon, M., Andreasen, N. C., & Prins, N. D. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.2 · Cited by 6
A Review on Current Strategies and Future Perspective in Respect to Alzheimer’s Disease Treatment
Bais, S., Kumari, R., & Prashar, Y. (2015) · Current Research in Neuroscience · doi:10.3923/crn.2016.1.15 · Cited by 6
Olsson, B., Schott, J. M., Blennow, K., & Zetterberg, H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341311 · Cited by 7
Self-citationLewis, T. J., & Trempe, C. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812112-2.00007-0 · Cited by 8
Antibody therapy for Alzheimer's disease
Tabira, T., Matsumoto, S., & Jin, H. (2011) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.51.1160 · Cited by 6
Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened
Knopman, D. S. (2018) · Neurology · doi:10.1212/wnl.0000000000005073 · Cited by 5
Sotoudeh, H., Alizadeh, M., Shahidi, R., Shobeiri, P., love, N., & Singhal, A. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.10.023 · Cited by 5
Asari, Y., Yasaka, K., Endo, K., Kanzawa, J., Okimoto, N., Watanabe, Y., Suzuki, Y., Amemiya, S., Kiryu, S., & Abe, O. (2025) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-025-01522-6 · Cited by 5
Prevention of Cognitive Decline
Gutierrez, J., & Isaacson, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3106-0_12 · Cited by 5
Neuroimaging of therapy-associated brain tissue abnormalities
Linn, J. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000108 · Cited by 5
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab
Russu, A., Samtani, M. N., Xu, S. X., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S. V., Liu, E., Brashear, H. R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151065 · Cited by 5
Self-citationProbabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease
Yang, K., & Chen, H.-H. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160129095012 · Cited by 5
Alzheimer’s Disease: Clinical Trials and the Amyloid Hypothesis
Cummings, J. L. (2011) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v40n7p304 · Cited by 5
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
Zetterberg, H., & Schott, J. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_11 · Cited by 5
The Ups and Downs of Amyloid in Alzheimer's
Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5
Oxidative Stress in Neurodegenerative Diseases
Alami, M., Fülöp, T., Boumezough, K., Khalil, A., Zerif, E., & Berrougui, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-69962-7_4 · Cited by 6
Novel immunological approaches for the treatment of Alzheimer's disease.
Sabharwal, P., & Wısnıewskı, T. (2014) · PubMed · doi:10.3969/j.issn.1672-6731.2014.03.001 · Cited by 5
Emerging Therapeutic Strategies in Alzheimer's Disease
Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5
Alzheimer's disease: New therapeutic strategies
Villegas, S. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2014.05.012 · Cited by 5
Frisoni, G. B. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70021-2 · Cited by 5
Engineering nanobodies for drug delivery systems in Alzheimer’s disease
Jootar, T., Hongeng, S., & Chiangjong, W. (2026) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2026.2617707 · Cited by 4
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 4
Jeong, S. Y., Suh, C. H., Lim, J., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2024.0140 · Cited by 4
Novak, G., & Einstein, S. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00004-4 · Cited by 4
The role of animal models in advancing amyloid-beta immunotherapy to the clinic
Games, D., & Seubert, P. A. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt46 · Cited by 4
Smith, A. F., Klotz, A., & Wormstone, I. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.001 · Cited by 4
Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials
Tortelli, R., Seripa, D., Panza, F., Solfrizzi, V., & Logroscino, G. (2016) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000445453 · Cited by 4
Passive Immunotherapy in Alzheimer’s Disease
Dolan, P. J., & Zago, W. M. (2018) · InTech eBooks · doi:10.5772/intechopen.76299 · Cited by 4
Mondal, A. C., & Sushma (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666211228100955 · Cited by 4
Passive immunotherapy - a viable treatment for Alzheimer's disease.
Yi, K. (2014) · PubMed · Cited by 4
Cerebral microbleeds in relation to cerebral amyloidangiopathy
Khan, M. A., Viswanathan, A., & Greenberg, S. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974892.015 · Cited by 4
Metadata
- Authors
- Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., Mulnard, R., Barakos, J., Gregg, K. M., Liu, E., Lieberburg, I., Schenk, D., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Butler Hospital (S.S.), Providence, RI; Brigham & Women's Hospital (R.S.), Boston, MA; University of Michigan (S.G.), Ann Arbor; UCL (N.C.F.), Institute of Neurology, London, UK; University of Göteborg (K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; VA Medical Center (M.R.), Seattle, WA; Cleo Roberts Center for Clinical Research/Sun Health Research Institute (M.S.), Sun City, AZ; Columbia University (L.S.H.), New York, NY; Baylor College of Medicine (R.D.), Houston, TX; Yale...
- Venue
- Neurology
- Published
- 2009-12-15
- Volume
- 73
- Issue
- 24
- Pages
- 2061-2070
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2790221
- OpenAlex
- W2086572083
- Cited by
- 753
- References
- 40
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 34 · 2021: 21 · 2020: 30 · 2019: 30 · 2018: 26 · 2017: 30 · 2016: 45 · 2015: 52 · 2014: 71 · 2013: 78 · 2012: 91
- FWCI
- 55.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Pfizer
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institutes of Health (5r03ag023916-02, 5r01ag007370-30, 1r41ns056856-01a2, 5u01ag024904-10)
- U.S. Public Health Service (UO1AGO24904)
- National Institute on Alcohol Abuse and Alcoholism (RL1AA017536)
- National Institute on Aging (U01-AG-024904, R01AG030457, R01AG14763, AG 08671, 1-R01-AG030457-01A1, P01AG007232, R01AG026114, U01AG016976, R01-AG007370, R43AG033474, U01AG010483, U01-AG 16976, 1-UO1-AG024904, 1 R03 AG023916-01A1, P01AG030004, P50AG008702, R01AG027435, R01AG017761, P01AG07232, P50AG008671, P30AG019610, P30 P3-AG 019610, P50AG005136, P50AG005134, U01AG032438, P50 AG08671, 5-U01-AG10483, AG06036-13, P50AG08702)
- National Heart, Lung, and Blood Institute (R01HL091099)
- National Institute of Mental Health (1 R01 MH58620-01A2, P50MH068789, R01MH058620)
- National Institute of Diabetes and Digestive and Kidney Diseases (IR21DK062098)
- National Institute of Neurological Disorders and Stroke (P01 NS 15655, P01NS015655, R01NS042859, T32NS007224)
- National Center for Research Resources (U54RR024350-01, P20RR020626)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, amyloid-beta, vasogenic edema, APOE ε4 carriers, cognitive decline, functional decline, dose escalation, treatment efficacy, drug safety
- MeSH terms
- Aged, Alzheimer Disease, Antibodies, Monoclonal, Brain, Brain Edema, Cognition, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Severity of Illness Index, Biomarkers, Treatment Outcome, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
